ELENI ZOBOLAS: Open Payments
NPI 1205277415 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$566 in 21 payments from 9 companies in 2025. Trend: 2023 $707 · 2024 $1,824 · 2025 $566
Food & beverage: $566
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 5 | $134 |
| Dendreon Pharmaceuticals LLC | 4 | $132 |
| Janssen Biotech, Inc. | 3 | $105 |
| PFIZER INC. | 3 | $64 |
| Merck Sharp & Dohme LLC | 2 | $45 |
| Novartis Pharmaceuticals Corporation | 1 | $27 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $23 |
| ABBVIE INC. | 1 | $21 |
| 180 Medical, Inc. | 1 | $15 |
Products named: GEMTESA, PROVENGE, ERLEADA, XTANDI, KEYTRUDA, PLUVICTO, JOURNAVX, LUPRON DEPOT.
Industry payments across NY — which companies pay providers there.
